<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052932</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-301</org_study_id>
    <nct_id>NCT04052932</nct_id>
  </id_info>
  <brief_title>A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout</brief_title>
  <official_title>A Phase3, Multicentre, Randomized, Double-Blind, Allopurinol and Placebo-Controlled Study to Evaluate the Efficacy and Safety of SHR4640 Monotherapy in Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to
      placebo and Allopurinol in patients with gout
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with a serum uric level≤360μmol/l.</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of subjects with a serum uric level≤360μmol/l.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a serum uric level≤360μmol/l</measure>
    <time_frame>Week 36</time_frame>
    <description>Proportion of subjects with a serum uric level≤360μmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in serum uric level</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Percentage change from baseline in serum uric level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual change from baseline in serum uric level</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Actual change from baseline in serum uric level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a serum uric level≤360μmol/l</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Proportion of subjects with a serum uric level≤360μmol/l</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">880</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once a day, orally, for 12 weeks, followed by SHR4640 treatment to 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR4640 dose1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR4640 dose1 once a day, orally, for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR4640 dose2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR4640 dose2 once a day, orally, for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol 300mg (milligram) once a day, Orally, for 36 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640 dose1</intervention_name>
    <description>tablets，dose1，QD</description>
    <arm_group_label>SHR4640 dose1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640 dose2</intervention_name>
    <description>tablets，dose2，QD</description>
    <arm_group_label>SHR4640 dose2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>tablets，QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol 300 MG</intervention_name>
    <description>tablets，300mg，QD</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject who met 1977 or 2015 ACR (American College of Rheumatology) classification of
             Gout and has a serum acid ≥ 480 μmol/L at screening;

          2. 18 kg/m2 ≤Body mass index (BMI)≤ 35 kg/m2

        Exclusion Criteria:

          1. Subject who is pregnant or breastfeeding;

          2. Alanine aminotransferase or Aspartate aminotransferase or total bilirubin&gt;1.5 upper
             normal limit;

          3. Subject with a positive test for HLA-B*5801;

          4. Estimated glomerular filtration rate (MDRD formula) &lt;60ml/min;

          5. HbA1c&gt;8%;

          6. Subject with known hypersensitivity or allergy to SHR4640 and allopurinal, or any
             component of SHR4640;

          7. Subject with kidney stones or suspicion of kidney stones;

          8. Subject who has acute gout flares within 2 weeks before randomization;

          9. Subject with a history of malignancy within the previous 5 years;

         10. Subject with a history of active peptic ulcer within a year;

         11. Subject with a history of xanthine urine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunde Bao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiaotong University, School of Medicine, Renji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Shen, PhD</last_name>
    <phone>021-61069103</phone>
    <email>shenyang@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rui Ning, PhD</last_name>
    <email>ningrui@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Jiaotong University, School of Medicine, Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunde Bao</last_name>
      <email>baochunde_1678@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

